Robert Cowan, MD, on Sex and Race Disparities in Migraine Patients
Subgroup disparities such as sex and race are more significant among patients with migraine, according to the results of a recent study presented at the American Academy of Neurology (AAN) 2021 Virtual Meeting. The researchers utilized data from an annual cross-sectional patient chart audit of 1003 patients who were recently prescribed a calcitonin gene-related peptide […]
Chart review finds ’significant differences’ in migraine management by race, sex
Migraine diagnoses, treatment and management varied by race and sex among a sample of patients that was “evenly distributed” across the country, according to researchers. Robert Cowan, MD, FAAN, chief of the division of headache medicine and professor of neurology at Stanford University, presented findings of the cross-sectional chart review at the American Academy of Neurology […]
Understanding the Impact of Sex and Race on the Migraine Patient’s Journey in the United States: Analyses From an Annual Cross-Sectional Patient Chart Audit
Authors: Robert P. Cowan, MD, FAAN; Meg M. Stabb; Nicholas W. Robinson, PhD; Virginia R. Schobel, MSc OBJECTIVE: To determine whether subgroup disparities recognized in general society are reflected in subpopulations with migraine. BACKGROUND: It has been widely observed that disparities exist between various sub-groups in the U.S., including commonly noted disparities based on sex […]
Patients with Not Active Progressive Multiple Sclerosis in the United States: Profiling an Underserved Segment
Authors: Virginia R. Schobel, MSc; Meg M. Stabb OBJECTIVE: Compare clinical presentation, treatment history, and drivers of therapy choice of active and not active patients with progressive multiple sclerosis (MS). BACKGROUND: No disease-modifying therapy (DMT) is currently approved in the US for not active progressive MS, although multiple agents are currently in late-stage clinical development. […]
Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds
From: Multiple Sclerosis News Today By: Marta Figueiredo, PhD Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS) patients switching treatment, according to the latest Spherix Global Insights’ report…(read more).
Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains largely virtual, and many practices are unlikely to return to pre-pandemic volumes EXTON, Pa., April 7, 2021 /PRNewswire/ — Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the […]
Bristol Myers Squibb’s Zeposia and Biogen’s Vumerity Place Competitive Pressure on Established Brands in the Multiple Sclerosis Switch Segment, According to Spherix Global Insights
While early patterns suggest that Genentech’s Ocrevus largely evades newcomer Novartis’ Kesimpta, COVID-19-related shifts in prescribing may be the real concern for the brand EXTON, Pa., March 31, 2021/PRNewswire/ — Biogen’s Tecfidera, Novartis’ Gilenya, and Genentech’s Ocrevus have all faced extensive competitive pressure over the past year due to launches of generics and new brands […]
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry, particularly when it comes to in-person promotion EXTON, Pa., February 12, 2021 /PRNewswire/ — Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global […]
Biogen’s Vumerity and Bristol Myers Squibb’s Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents
According to Spherix Global Insights, the emerging Bruton’s tyrosine kinase inhibitors, including EMD Serono’s evobrutinib, Sanofi Genzyme’s tolebrutinib, and Genentech’s fenebrutinib, may disrupt current first-line treatment patterns, particularly in progressive multiple sclerosis EXTON, Pa., February 11, 2021/PRNewswire/ —With the recent additions of Novartis’ Mayzent, Bristol Myers Squibb’s Zeposia, and Biogen’s Vumerity to the multiple sclerosis […]
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) and Zeposia (BMS) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis EXTON, Pa., January 29, 2020 /PRNewswire/ —Spherix Global Insights, a […]
